A prediction model for worsening diabetic retinopathy after panretinal photocoagulation

Jinglan Li1,2†, Xuanlong Li1,2†, Mingxing Lei1†, Wanyue Li1,2, Wenqian Chen2, Tianju Ma2, Yi Gao2, Zi Ye2 and Zhaohui Li2*

Abstract

Background: As one of the severe complications of diabetes mellitus, diabetic retinopathy (DR) is the leading cause of blindness in the working age worldwide. Although panretinal photocoagulation (PRP) was standard treatment, PRP-treated DR still has a high risk of progression. Hence, this study aimed to assess the risk factors and establish a model for predicting worsening diabetic retinopathy (DR-worsening) within five years after PRP.

Methods: Patients who were diagnosed with severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and treated with PRP were included; and those patients were randomly assigned to either a training or validation cohort. The multivariate logistic regression analysis was used to screen potential risk factors for DR-worsening in the training cohort. Then the model was established after including significant independent risk factors and further validated using discrimination and calibration.

Results: A total of 271 patients were included, and 56.46% of patients had an outcome of DR-worsening. In the training cohort (n = 135), age (odds ratio [OR] = 0.94, 95% confidence interval [CI] 0.90–0.98), baseline best corrected visual acuity (logMAR) (OR = 10.74, 95% CI 1.84–62.52), diabetic nephropathy (OR = 9.32, 95% CI 1.49–58.46), and hyperlipidemia (OR = 3.34, 95% CI 1.05–10.66) were screened out as the independent risk factors, which were incorporated into the predictive model. The area under the receiver operating characteristic curve and calibration slope in the training and validation cohort were 0.79, 0.96 (95% CI 0.60–1.31), and 0.79, 1.00 (95% CI 0.66–1.34), respectively. Two risk groups were developed depending on the best cut-off value of the predicted probability, and the actual probability was 34.90% and 82.79% in the low-risk and high-risk groups, respectively (P < 0.001).

Conclusions: This study developed and internally validated a new model to predict the probability of DR-worsening after PRP treatment within five years. The model can be used as a rapid risk assessment system for clinical prediction of DR-worsening and identify individuals at a high risk of DR-worsening at an early stage and prescribe additional treatment.

Keywords: Diabetic retinopathy, Panretinal photocoagulation, Risk factors, Prediction model

Background

Diabetic retinopathy (DR), one of the most common microvascular complications of diabetes mellitus, is the leading cause of blindness and visual impairment in the working age (20–65 years) worldwide [1, 2]. It is classified as non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) based on the proliferative status of retinal neovascularization [3]. PDR could be followed by serious complications, such as...
vitreous hemorrhage, tractional retinal detachment, and neovascular glaucoma, a more advanced stage with a risk of poor vision outcome [4, 5].

Panretinal photocoagulation (PRP) is currently the standard treatment for PDR and severe NPDR, which was recommended in previous clinical trials [6, 7]. With proper treatment including PRP, PDR patients have a 90% reduced risk of blindness within five years [8]. However, PRP is far from a “one-and-done treatment”, 45% of the eyes required supplemental PRP, intravitreal anti-vascular endothelial growth factor (VEGF) injection, or even vitrectomy, within two years after PRP treatment [9, 10]. Those patients usually suffered from very poor visual prognosis, even blindness [11–13]. Identification of risk factors associated with progression after PRP would be beneficial to guide preventive and therapeutic strategies among PRP-treated DR patients.

Currently, several risk factors have been proposed to be associated with DR-worsening, including age, uncontrolled diabetes, renal dysfunction, lipid metabolic abnormalities, anemia, etc. [14–18]. Although these factors can provide guidance in clinical management, they cannot accurately predict the specific risk of DR-worsening. In addition, studies on prediction of the prognosis of PRP are very scarce, and without a definitive conclusion. Risk factors identified from DR-worsening patients might not be applicable among PRP-treated DR patients. Thus, it is of great clinical significance to investigate the potential risk factors associated with DR-worsening in particular after PRP treatment. Furthermore, to achieve risk stratification and subsequently perform individualized prevention, it is urgent to develop a model to predict the risk probability of DR-worsening specifically among this population.

Therefore, this study aimed to develop a model to predict the progression of DR after PRP to prevent it better and earlier. This study speculated that the model could reflect the relationships between DR-worsening and its potential risk factors and quantify the contribution of these factors by correlation coefficients.

**Methods**

**Study population**

The patients included in our study were all diagnosed with PDR or severe NPDR and treated with PRP at Chinese PLA General Hospital between 1 January 2008 and 1 January 2021 (n = 2519). Patient’s clinical data were extracted and collected from the hospital electronic medical record system. Only one eye of every patient was included in the study, and the eye with more severe DR or lower vision was included if both two eyes met the criteria for inclusion. The data were collected and recorded by two experienced ophthalmologists to guarantee data quality. When disagreements occurred, they were resolved through discussion. Patients were excluded if they met any of the following criteria: (1) Missing the outcome of DR within five years; (2) Received anti-VEGF treatment before or after PRP; (3) Having a history of the laser before PRP; (4) Having the history of intraocular surgery other than cataract surgery; (5) Having the history of other retinal diseases, such as age-related macular degeneration, retinal artery/vein occlusion, ischemic optic neuropathy, posterior uveitis, glaucoma, or other eye diseases that affected fundus examination; (6) Missing clinical information. After exclusion, 271 patients were included in this study (Fig. 1).

Treatment of severe NPDR and PDR was performed according to guidelines [19]. According to ETDRS protocol [20], a standard argon-type laser was used in PRP, with the recommended settings including 1200 to 1600 spots, approximately 400 μm burning in size, 200 mW power, and 100 ms pulse duration. PRP was administered across four treatment sessions, one session per week. Finally, laser burn spots were scattered evenly across the retina almost to the equator and away from the macula [20].

This study was conducted in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the Ethics Committee of Chinese PLA General Hospital (no. S2021-068-01). Patient consent for inclusion was waived because all data were anonymized and the study was retrospective in nature.

![Fig. 1 The flow chart](image-url)
Outcomes and definitions
The positive outcome was DR-worsening within five years after PRP treatment. The patient was considered to have a positive outcome if any of the following situations occurred to them within five years: vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma, requiring further PRP, intravitreal anti-VEGF injection, or vitrectomy. The negative outcome was non-DR-worsening, meaning that the above conditions did not occur within five years, and the vision remained stable (the decline was not more than two lines). Patients were followed until the occurrence of the outcome, loss to follow-up, or administrative censoring, whichever came first. The last follow-up date was 1 August 2021.

Risk factors
The study included the following 29 potential risk factors for predicting post-PRP progression of DR: (1) Ocular parameters: stage of diabetic retinopathy (PDR or severe NPDR); baseline best corrected visual acuity (BCVA); (2) Clinical case data: age; sex; type of diabetes (type 1 or type 2); diabetes duration; diabetic nephropathy; diabetes neuropathy; coronary heart disease; prior stroke; hyperlipidemia; grade of hypertension (0–3); body mass index; (3) Laboratory parameters: homocysteine; fasting blood glucose; urea; creatinine; uric acid; total cholesterol; triglyceride; high-density lipoprotein; low-density lipoprotein; serum superoxide dismutase; glycosylated serum protein; serum cystatin C; hemoglobin; hematocrit; platelet; neutrophil/lymphocyte ratio.

Ocular parameters were assessed at baseline by recording BCVA, intraocular pressure, slit-lamp examination, retinal examination, and fundus photograph. Baseline BCVA was assessed with the Snellen chart and expressed in logMAR values. Detailed fundus examination was performed by the trained ophthalmologist using direct and indirect ophthalmoscope. Fundus fluorescein angiography was performed before laser treatment to identify suspicious but clinically insignificant retinal neovascularization which was the most reliable and important evidence for the PDR. Macular OCT can determine macular edema or other macular lesions, and B ultrasound can determine retinal detachment and fibrous membrane hyperplasia. Ophthalmic evaluation was conducted by a single retina specialist, stereoscopic fundus photography and fundus fluorescein angiography were conducted by a single examiner.

Diabetic nephropathy was defined as urinary albumin creatinine ratio ≥ 30 mg/g in the absence of other primary causes of kidney damage [21]. Diabetic neuropathy was tested with a 128-Hz tuning fork for vibration sense and a 10-g monofilament test for light touch perception (on four sites per foot) [22]. Hyperlipidemia was defined as total cholesterol ≥ 6.2 mmol/L or triglyceride ≥ 2.3 mmol/L or low-density lipoprotein ≥ 4.1 mmol/L or high-density lipoprotein < 1.0 mmol/L [23]. Coronary heart disease and prior stroke were judged by inquiring about the medical history and referring to their medical records. Venous blood was taken from all patients on an empty stomach to detect biochemistry and blood routine.

Statistical analysis
In the study, normally distributed continuous variables were expressed as mean ± standard deviation, non-normally distributed continuous variables were presented as median with the quartile range, and categorical variables were summarized as proportion (%). Using the Kolmogorov–Smirnov test or Shapiro–Wilk test to determine if each variable had a normal distribution. Baseline characteristics of patients were compared between groups using the Chi-square test for categorical variables, the Student’s T-test or the Mann–Whitney test for continuous variables, as appropriate. Statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC) and IBM SPSS 23.0 (IBM Corp, Armonk, NY, USA) for Windows XP. P < 0.05 was considered statistically significant (* P < 0.05, ** P < 0.01).

All the included patients were randomly assigned to either the training cohort or validation cohort. Univariate and multivariate logistic regression analysis was respectively used to analyze the potential risk factors of DR-worsening in the training cohort, and the risk factors identified by the univariate analysis (P < 0.20) entered into the multivariate analysis. The model was established depending on the training cohort subsequently, and significant risk factors identified by the multivariate analysis (stepwise selection) were enrolled to create the model.

The model was developed as follows:

\[
P(Y = 1) = \frac{e^{(\text{intercept} + a_1x_1 + bx_2 + cx_3 + dx_4)}}{(1 + e^{(\text{intercept} + a_1x_1 + bx_2 + cx_3 + dx_4)})}.
\]

\(P(Y = 1)\) represented the predicted probability of DR-worsening, and \(a_1, b, c,\) and \(d\) were the corresponding estimates of the included factors.

Discrimination and calibration in both training and validation cohorts were used to evaluate the performance of the model. The discriminative capability of the model to distinguish patients with and without DR-worsening was mainly assessed by the area under the receiver operating characteristic curve (AUROC) and discrimination slope. The discriminative slope was defined as the mean difference in the predicted probabilities of developing
DR-worsening between patients actually with DR-worsening and without DR-worsening. Besides, the correct classification rate (CCR), sensitivity, and specificity were also used to evaluate the formula’s discrimination. Furthermore, the consistency between predicted and actual observed probability of DR-worsening was defined as the calibration of the model, and it was evaluated based on the calibration curve. In addition, the formula’s calibration was also evaluated by the Hosmer–Lemeshow goodness-of-fit test, and \( P > 0.05 \) in the goodness-of-fit statistics indicated a favorable match between predicted and observed actual probability of DR-worsening.

Each patient had an actual probability of DR-worsening and a predicted probability that was calculated using the model. Based on the best cut-off value of the predicted probability depending on the largest sum of sensitivity and specificity, all patients were divided into a low-risk group and a high-risk group. We further calculated and compared the difference between actual probability of DR-worsening of the two risk groups.

**Results**

**Patient’s characteristics**

A total of 271 patients were enrolled with a mean age of 50.69±11.24 years and 58.30% of them were men. The majority of comorbidity was hypertension (73.80%), followed by hyperlipidemia (27.68%), diabetic nephropathy (26.57%), coronary heart disease (8.86%), diabetic neuropathy (8.12%), and prior stroke (5.17%). The demographics and laboratory parameters of patients are presented in Table 1. The incidence of DR-worsening was 56.46%, and 153 patients were included in the DR-worsening group, including 112 eyes with vitreous hemorrhage, 26 eyes with vitreous hemorrhage and retinal detachment, seven eyes with secondary glaucoma and retinal detachment, four eyes with vitreous hemorrhage and macular edema, two eyes with secondary glaucoma and macular edema, and two eyes with secondary glaucoma, within five years after PRP treatment.

Compared with the non-DR-worsening group, patients with the DR-worsening outcome were more likely to be younger, have lower baseline BCVA (or higher logMAR BCVA), have more frequency of diabetic nephropathy, diabetic neuropathy, and hyperlipidemia, and the differences in laboratory parameters related to renal function (creatinine, urea, uric acid, serum cystatin C) and anemia (hemoglobin, hematocrit) were also statistically significant (\( P < 0.05 \)). In addition, the proportion of males and PDR, fasting blood glucose, homocysteine, and neutrophil/lymphocyte ratio was higher in patients with DR-worsening, and regarding blood lipids, total cholesterol, triglycerides, and low-density lipoprotein were also higher in patients with DR-worsening vs. non-DR-worsening, but the differences were not statistically significant (\( P > 0.05 \)). The detail about the comparison of DR-worsening and non-DR-worsening is presented in Table 1.

**Model development**

The baseline characteristics of patients in the training cohort (\( n = 135 \)) and validation cohort (\( n = 136 \)) are shown in Additional file 1: Table S1. There were no statistically significant differences between the training cohort and the validation cohort in all the 29 risk factors (\( P > 0.05 \)), indicating that patients in the two cohorts were comparable. In the training cohort, univariate analysis was used to analyze the potential risk factors of DR-worsening, then multivariate analysis was conducted after including 15 variables (\( P < 0.20 \) according to the univariate analysis), and the significant risk factors were defined by the result of multivariate analysis finally. The results of univariate and multivariate logistic regression analysis are shown in Table 2. It indicated that the following factors were all independent risk factors for DR-worsening: age (OR=0.94, 95% CI 0.90–0.98), baseline BCVA (logMAR) (OR=10.74, 95% CI 1.84–62.52), diabetic nephropathy (OR=9.32, 95% CI 1.49–58.46), and hyperlipidemia (OR=3.34, 95% CI 1.05–10.66). All the above four variables were considered and incorporated into the construction of the predictive model of DR-worsening depending on the result of stepwise regression. Finally, a model was developed as presented in Table 3. According to the model, lower age, lower baseline BCVA (or higher logMAR BCVA), diabetic nephropathy, and hyperlipidemia were associated with a significantly higher incidence of DR-worsening, which was in line with the result of COX regression analysis (Additional file 1: Table S2).

A calculator was used to facilitate the utility of the model in clinical practice (Additional file 2). The calculation formula was developed as follows:

\[
P(Y = 1) = \frac{e^{(1.15 - 0.05x1 + 2.08x2 + 2.09x3 + 0.97x4)}}{1 + e^{(1.15 - 0.05x1 + 2.08x2 + 2.09x3 + 0.97x4)}}
\]

In the model, \( x1 \) indicated hyperlipidemia, \( x2 \) indicated baseline BCVA (logMAR), \( x3 \) indicated diabetic nephropathy, and \( x4 \) indicated hyperlipidemia. \( P(Y = 1) \) indicated the probability of DR-worsening as predicted.
by the model. An example was shown as follows: If a 52-year-old patient ($x_1 = 52$) with a baseline BCVA (logMAR) of 1.00 ($x_2 = 1.00$) and hyperlipidemia ($x_4 = 1$) and without diabetic nephropathy ($x_3 = 0$), then the predicted probability of DR-worsening was $P(Y = 1) = e^{1.15 - 0.05x_1 + 2.08x_2 + 2.09x_3 + 0.97x_4}/(1 + e^{1.15 - 0.05x_1 + 2.08x_2 + 2.09x_3 + 0.97x_4}) = 83.20\%$.

### Model validation

The AUROC of the prediction model was 0.79 in the training cohort (Fig. 2A) and 0.79 in the validation cohort (Fig. 2B), the discrimination slope was 0.28 (95% CI 0.20–0.35) in the training cohort and 0.29 (95% CI 0.21–0.37) in the validation cohort (Fig. 3), illustrating good discriminative ability of the prediction model. Compared with 71.90% in the training cohort, the

--

**Table 1** Patients' baseline characteristics

| Variables                        | Total patients (n = 271) | DR-worsening (n = 153) | Non-DR-worsening (n = 118) | P valuea |
|----------------------------------|-------------------------|------------------------|-----------------------------|----------|
| Age, years                       | 50.69 ± 11.24           | 49.16 ± 10.90          | 52.66 ± 11.42               | 0.011**  |
| Male, n (%)                      | 158 (58.30%)            | 95 (62.1%)             | 63 (53.4%)                  | 0.150    |
| Baseline BCVA (logMAR)           | 0.30 (0.10, 0.52)       | 0.40 (0.22, 0.70)      | 0.22 (0.10, 0.40)           | <0.001** |
| Diabetes duration, years         | 12.24 ± 7.37            | 11.92 ± 7.26           | 12.64 ± 7.52                | 0.524    |
| Type 2 diabetes, n (%)           | 261 (96.31%)            | 145 (94.8%)            | 116 (98.3%)                 | 0.127    |
| PDR, n (%)                       | 169 (62.36%)            | 98 (64.1%)             | 71 (60.2%)                  | 0.324    |
| Diabetic nephropathy, n (%)      | 72 (26.57%)             | 65 (42.5%)             | 7 (5.9%)                    | <0.001** |
| Diabetic neuropathy, n (%)       | 22 (8.12%)              | 19 (12.4%)             | 3 (2.5%)                    | 0.003**  |
| Coronary heart disease, n (%)    | 24 (8.86%)              | 17 (11.1%)             | 9 (7.6%)                    | 0.335    |
| Prior Stroke, n (%)              | 14 (5.17%)              | 8 (5.2%)               | 6 (5.1%)                    | 0.958    |
| Hyperlipidemia, n (%)            | 75 (27.68%)             | 59 (38.6%)             | 16 (13.6%)                  | <0.001** |

| Hypertension, n (%)              | 71 (26.20%)             | 40 (26.1%)             | 31 (26.3%)                  | 0.111    |
|                                 | 83 (30.63%)             | 41 (26.8%)             | 42 (35.6%)                  |          |
|                                 | 48 (17.71%)             | 23 (15.0%)             | 25 (21.2%)                  |          |
|                                 | 69 (25.46%)             | 49 (32.0%)             | 20 (16.9%)                  |          |
| BMI, kg/m²                       | 25.52 ± 3.42            | 25.46 ± 3.67           | 25.60 ± 3.09                | 0.732    |
| Homocysteine, umol/L             | 13.34 ± 7.91            | 14.14 ± 9.40           | 12.29 ± 5.27                | 0.061    |
| Fasting blood glucose, mmol/L    | 6.96 ± 2.77             | 7.18 ± 2.81            | 6.67 ± 2.71                 | 0.085    |
| Urea, umol/L                     | 6.66 ± 3.86             | 7.58 ± 4.78            | 5.47 ± 1.47                 | <0.001** |
| Creatinine, mmol/L               | 71.40 (56.70, 92.50)    | 76.20 (61.15, 110.50)  | 66.30 (54.83, 79.75)        | <0.001** |
| Uric acid, umol/L                | 327.98 ± 90.23          | 340.59 ± 89.91         | 311.64 ± 88.37              | 0.009**  |
| Total cholesterol, mmol/L        | 4.36 ± 1.18             | 4.49 ± 1.36            | 4.18 ± 0.89                 | 0.090    |
| Triglyceride, mmol/L             | 1.18 (0.88, 1.75)       | 1.27 (0.87, 1.98)      | 1.15 (0.89, 1.57)           | 0.139    |
| High-density lipoprotein, mmol/L | 1.13 ± 0.34             | 1.13 ± 0.35            | 1.12 ± 0.32                 | 0.92     |
| Low-density lipoprotein, mmol/L  | 2.76 ± 0.97             | 2.82 ± 1.10            | 2.67 ± 0.78                 | 0.281    |
| Serum superoxide dismutase, U/ML | 146.23 ± 27.01          | 144.44 ± 30.87         | 148.56 ± 20.87              | 0.076    |
| Glycosylated serum protein, umol/L| 228.91 ± 75.04         | 228.53 ± 82.28         | 229.39 ± 64.80              | 0.986    |
| Serum cystatin C, mg/L           | 1.04 (0.87, 1.27)       | 1.11 (0.89, 1.41)      | 0.97 (0.86, 1.11)           | <0.001** |
| Hemoglobin, g/L                  | 129.58 ± 18.91          | 127.04 ± 20.54         | 132.88 ± 16.07              | 0.044**  |
| Hematocrit                        | 0.38 ± 0.05             | 0.37 ± 0.06            | 0.39 ± 0.04                 | 0.026*   |
| Platelet, 10^9/L                  | 215.19 ± 61.32          | 213.56 ± 64.11         | 217.31 ± 57.69              | 0.613    |
| Neutrophil/lymphocyte ratio      | 1.91 (1.47, 2.57)       | 1.97 (1.53, 2.76)      | 1.81 (1.39, 2.25)           | 0.017*   |

Values are expressed as mean ± SD, median with inter-quartile range, or n (%)

BCVA best corrected visual acuity, DR diabetic retinopathy, PDR proliferative diabetic retinopathy, BMI body mass index

*P<0.05, **P<0.01

* For comparison between DR-worsening and non-DR-worsening
CCR was 71.30% in the validation cohort. Other metrics including sensitivity and specificity are shown in Table 4.

When considering the calibration ability of the model, the calibration slopes in the training and validation cohort were 0.96 (95% CI 0.60–1.31) (Fig. 4A, C) and 1.00 (95% CI 0.66–1.34) (Fig. 4B, D) respectively, the X-intercept and Y-intercept were both very close to 0, indicating that model had good calibration ability. Moreover, the $P$ values for Hosmer–Lemeshow goodness-of-fit tests were 0.34 and 0.84 in the training and validation cohort respectively (Table 5). A $P$ value of more than 0.05 in the goodness-of-fit test indicates that the consistency between the predicted and observed probability is good. Conversely, a $P$ value of less than 0.05 indicates poor

---

### Table 2 Univariate and multivariate analysis of patient’s characteristics for predicting DR-worsening

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
| Age                        | 0.95 (0.93, 0.98)   | 0.94 (0.90, 0.98)     |
| Sex                        | 0.62 (0.31, 1.24)   | 0.72 (0.25, 2.07)     |
| Baseline BCVA (logMAR)     | 6.72 (2.78, 16.25)  | 10.74 (1.84, 62.52)   |
| Diabetes duration          | 0.99 (0.94, 1.04)   | 0.59 (0.03, 10.07)    |
| Type of diabetes           | 0.23 (0.03, 2.02)   | 0.96 (0.36, 2.51)     |
| Stage of DR                | 1.64 (0.80, 3.37)   | 2.48 (0.33, 18.64)    |
| Diabetic nephropathy       | 11.11 (3.17, 38.89) | 3.34 (1.05, 10.66)    |
| Diabetic neuropathy        | 4.09 (0.85, 19.68)  | 1.07 (0.94, 1.22)     |
| Coronary heart disease     | 1.36 (0.42, 4.39)   | 0.59 (0.03, 10.07)    |
| Prior Stroke               | 0.82 (0.11, 5.99)   | 0.96 (0.36, 2.51)     |
| Hyperlipidemia             | 4.40 (1.89, 10.24)  | 2.48 (0.33, 18.64)    |
| Hypertension               | 1.11 (0.82, 1.50)   | 0.59 (0.25, 1.31)     |
| BMI                        | 0.99 (0.90, 1.08)   | 0.59 (0.25, 1.31)     |
| Homocysteine               | 1.02 (0.97, 1.07)   | 0.59 (0.25, 1.31)     |
| Fasting blood glucose      | 1.10 (0.94, 1.22)   | 0.59 (0.25, 1.31)     |
| Urea                       | 1.01 (1.00, 1.02)   | 1.00 (0.99, 1.01)     |
| Creatinine                 | 1.41 (1.14, 1.74)   | 1.00 (0.99, 1.01)     |
| Uric acid                  | 1.00 (1.00, 1.01)   | 1.00 (0.99, 1.01)     |
| Total cholesterol          | 1.22 (0.90, 1.65)   | 0.95 (0.85, 1.07)     |
| Triglyceride               | 1.18 (0.87, 1.61)   | 1.06 (0.83, 1.34)     |
| High-density lipoprotein   | 1.24 (0.48, 3.24)   | 0.95 (0.83, 1.07)     |
| Low-density lipoprotein    | 1.10 (0.77, 1.58)   | 0.95 (0.83, 1.07)     |
| Serum superoxide dismutase| 1.00 (0.99, 1.02)   | 1.00 (0.99, 1.01)     |
| Glycosylated serum protein | 1.00 (1.00, 1.01)   | 1.00 (0.99, 1.01)     |
| Serum cystatin C           | 3.31 (1.18, 9.31)   | 6.66 (2.12, 2.36)     |
| Hemoglobin                 | 0.99 (0.97, 1.01)   | 0.95 (0.85, 1.07)     |
| Hematocrit                 | 1.00 (0.99, 1.01)   | 1.00 (0.99, 1.01)     |
| Neutrophil/lymphocyte ratio| 1.21 (0.86, 1.68)   | 0.21 (0.13, 0.31)     |

**BCVA best corrected visual acuity, DR diabetic retinopathy, OR odds ratio, CI confidence interval, BMI body mass index**

* $P<0.05$, ** $P<0.01$
Fig. 2 The area under the receiver operating characteristic (AUROC) curve for the model: A the training cohort, B the validation cohort

Table 4 Discrimination performances of the model

| Cohort         | AUROC | Slope  | 95% CI  | P value | CCR   | Sensitivity | Specificity |
|----------------|-------|--------|---------|---------|-------|-------------|-------------|
| Training cohort| 0.79  | 0.28   | 0.20–0.35| <0.001  | 71.90%| 52.70%      | 95.10%      |
| Validation cohort| 0.79  | 0.29   | 0.21–0.37| <0.001  | 71.30%| 59.50%      | 87.70%      |

AUROC area under the receiver operating characteristic curve, CI confidential interval, CCR correct classification rate
Fig. 4 Plotting deciles of the predicted probability of DR-worsening against the observed probability for the model: A, C the training cohort; B, D the validation cohort. The x-axis is the predicted risk and the y-axis is the actual risk. The blue solid lines indicate the performance of the model, and a closer fit to the diagonal dotted lines indicates a better prediction.

Table 5 Calibration performances of the model

| Cohort          | Slope | 95% CI  | X-intercept | 95% CI | Y-intercept | 95% CI   | R squared | Goodness-of-fit test |
|-----------------|-------|---------|-------------|--------|-------------|----------|-----------|---------------------|
| Training cohort | 0.96  | 0.60 to 1.31 | −0.03  | −0.39 to 0.15 | 0.02 | −0.19 to 0.24 | 0.83 | 0.34                |
| Validation cohort | 1.00  | 0.66 to 1.34 | 0.00   | −0.31 to 0.17 | 0.00 | −0.22 to 0.21 | 0.85 | 0.84                |

CI: confident interval, X: x-axis, Y: y-axis
consistency. In the present study, \( P \) values were both above 0.05 in the training and validation cohorts, representing favorable consistency between predicted and observed probability of DR-worsening.

Risk stratification
According to the best cut-off value of the predicted probability, which was 47.11% and 62.15% in the training and validation cohort respectively, patients were divided into the low-risk group (0–55.00%) and high-risk group (above 55.00%) based on their mean value (55.00%) (Table 6). The predicted probability in the two groups was 35.31% and 82.29%, respectively. The corresponding actual probability was 34.90% (52/149) and 82.79% (101/122), respectively (\( P < 0.001 \)). In two groups, the observed actual probabilities were similar to the predicted probabilities of DR-worsening, indicating that the classification was reproducible.

### Discussion
This study investigated predictors of DR-worsening after PRP. After adjusting for various confounders, younger age, lower baseline BCVA (or higher logMAR BCVA), diabetic nephropathy, and hyperlipidemia were found to be independent predictors of a higher probability of DR-worsening after PRP. These four risk factors were then incorporated and developed into a new model to predict the risk of DR-worsening following PRP treatment within five years, which is convenient for clinicians and healthcare strategy makers to use. In addition, patients can be divided into a low-risk and high-risk group based on the probability of DR-worsening predicted by the model, which helps identify patients at a high risk of developing DR-worsening and prevent further loss of visual function.

Age at the onset of diabetes has been proved to be one of the key factors in the development and progression of PDR [24]. Studies have shown that younger patients with PDR had a higher risk of visual loss than older patients, and the onset age of type 2 diabetes under 45 years old was an independent risk factor for the development and progression of PDR [25, 26]. Previous studies have shown that more severe retinal proliferation, greater surgical difficulty, and lower anatomical reduction success rate due to rapid progression of retinal neovascularization could be found in younger PDR patients undergoing vitrectomy [27, 28]. The present study also reached a similar conclusion that younger age was an independent risk factor for DR-worsening after PRP. In addition, younger patients have higher prognostic requirements and economic burden associated with visual loss compared to the elderly. Therefore, age may be an important but often underappreciated prognostic factor of DR in clinical practice.

This study showed that DR progressed significantly after PRP treatment when the baseline BCVA was low. Increased visual loss is associated with increased DR severity [24], and thus once DR progressed, active treatment such as PRP or intravitreal anti-VEGF injection was one of the best ways to reduce DR-related blindness [29]. However, in the case of severe retinal ischemia, diffusion of oxygen needed by macular may remain insufficient and even lead to macular edema in spite of PRP, causing lower vision [15, 30]. This finding is also in line with the study that lower vision is associated with the larger avascular zone area of foveal in DR patients [31]. Therefore, prevention of DR-worsening may be an important strategy to reduce DR-related vision loss, even blindness.

In our study, the association of diabetic nephropathy with DR-worsening after PRP was observed to be statistically significant (\( P < 0.05 \) in both univariate and multivariate logistic regression analysis). In addition, the laboratory parameters related to renal function including creatinine, urea, and serum cystatin C had a statistically significant association with DR-worsening in the univariate logistic analysis, suggesting that with increasing severity of renal function there will be more likelihood of the DR-worsening. Furthermore, compared with the non-DR-worsening group, the patients in the DR-worsening group had worse kidney function and a greater frequency of diabetic nephropathy. Current studies have confirmed that diabetic nephropathy is closely related to DR, especially PDR or severe NPDR in diabetic patients [32–34]. Similarly, diabetic nephropathy was found to be an independent risk factor of DR-worsening after PRP. The pathophysiology of both DR and diabetic nephropathy is similar. The development of DR and diabetic nephropathy influences and promotes each other, which supports the view that the two diseases share a common etiological basis, and emphasizes that the treatment and

### Table 6 Classification of low-risk and high-risk groups

| Group                  | Patients (n = 271) | Predicted probability | Actual probability | \( P \) (chi-square) |
|------------------------|-------------------|-----------------------|--------------------|---------------------|
| Low-risk (0–55%)       | 149               | 35.31%                | 52/149 (34.90%)    | < 0.001             |
| High-risk (above 55%)  | 122               | 82.29%                | 101/122 (82.79%)   |                     |

\( a \) The rate of DR-worsening

\( b \) An actual probability of DR-worsening between the two risk groups
care of DR should be combined with a multidisciplinary integrated treatment management model [35].

Our study also found that hyperlipidemia was the risk factor for the presence of DR-worsening after PRP treatment. In recent years, hyperlipidemia has been considered one of the strongest risk factors for the occurrence and development of DR [36, 37]. As reported in some studies, lipid-lowering therapy reduced the progression of DR and the need for laser treatment [38, 39], and total cholesterol and low-density lipoprotein were risk factors for the occurrence of any DR [23]. In addition, poor control of serum triglycerides was associated with progression of PDR [40], indicating that intensive lipid control might be associated with better clinical prognosis of DR after PRP treatment.

There were some prediction models about progression of DR [41, 42] or complications of diabetes, such as diabetic nephropathy [43] and diabetic foot [44]. To the author's knowledge, no prediction model for DR patients with PRP treatment has been published, and studies on risk factors of the prognosis of PRP are also very scarce. Our model has four risk factors that are easy to obtain in medical records and further explores the interaction between these risk factors and DR-worsening, which have rarely been reported in previous studies and will provide a reference for future studies. Furthermore, the model can provide patients with an immediate and reliable assessment of DR-worsening within five years after PRP treatment. This estimation could guide clinicians to identify ones at a high risk of DR-worsening at an early stage and prescribe additional treatment, such as more frequent follow-up, supplemental laser photocoagulation therapy, or intravitreal anti-VEGF injection.

Nonetheless, the present study still had several limitations. Firstly, some studies have suggested that poor blood glucose control, long diabetes duration, hypertension, anemia, and other variables were also independent risk factors for DR-worsening [18, 45, 46]. However, this study did not produce similar results, possibly because patients with stable DR tended to lack regular review and even lose follow-up, which resulted in fewer patients in the non-DR-worsening group than in the DR-worsening group, and this might have introduced bias. In addition, this study was a retrospective analysis without standard diagnostic tests on patients among different doctors, and so was the collection of patient's comorbidities. Lastly, while this model is useful in internal validation, external validation is also necessary. Therefore, prospective and multicenter studies are warranted to confirm these findings.

Conclusion
In this study, the four independent risk factors, younger age, lower baseline BCVA (or higher logMAR BCVA), diabetic nephropathy, and hyperlipidemia, were found to be related to a higher probability of DR-worsening after PRP. This study developed and internally validated a new model to predict the probability of DR-worsening after PRP treatment within five years. The model can be used as a rapid risk assessment system for clinical prediction of DR-worsening and identify individuals at a high risk of DR-worsening at an early stage and prescribe additional treatment.

Abbreviations
AUROC: Area under the receiver operating characteristic curve; BCVA: Best corrected visual acuity; BMI: Body mass index; CCR: Correct classification rate; CI: Confidence interval; DR: Diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; OR: Odds ratio; PDR: Proliferative diabetic retinopathy; PRP: Pan-retinal photocoagulation; VEGF: Vascular endothelial growth factor.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13098-022-00892-z.

Acknowledgements
The authors thank all the patients in our study and the institution of Chinese PL A General Hospital, Beijing, China.

Author contributions
JL collected, identified, and cleaned the data, and wrote the main manuscript text. ML and XL made a statistical analysis of the data. WL, WC, TM, and YG collected the data. ZL and ZY conceived and designed the study. All authors reviewed the manuscript and all authors agree to be responsible for all aspects of the work. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Because we did not acquire consent from the patients in this study to share individual data publicly, health data of individuals cannot be available online for the public. However, the datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was conducted in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the Ethics Committee of Chinese PLA General Hospital (No. S2021-068-01). And patient consent for inclusion was waived because all data were anonymized and the study was retrospective in nature.

Additional file 1. Table S1 Characteristic comparison between the training and validation group. Table S2 COX regression analysis of total patients.

Additional file 2. A calculator to predict DR-worsening within five years after PRP.
References

1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vision (London, England). 2015;2:17. https://doi.org/10.1186/s40662-015-0026-2.

2. Yang QH, Zhang Y, Zhang XM, Li XR. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and Meta-analysis. Int J Ophthalmol. 2019;12(2):302–11. https://doi.org/10.3969/j.issn.2095-4200.2019.02.19.

3. Kollia AN, Liblau PW. Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107(5):75–83. https://doi.org/10.3238/ arztebl.2010.0075.

4. Bek T, Nielsen MS, Klug SE, Eriksen JE. Increasing metabolic variability increases the risk for vitreous in proliferative diabetic retinopathy. Int Ophthalmol. 2021. https://doi.org/10.1007/s11759-021-02049-3.

5. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799. https://doi.org/10.1016/j.redxbio.2020.101799.

6. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study. Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94(7):761–74. https://doi.org/10.1016/ s0161-6420(87)33527-4.

7. Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaeveri CD, Punjabi OS, et al. Effect of Intravitreal aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2020;324(23):2383–95. https://doi.org/10.1001/jama.2020.23027.

8. Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2021;21(9):35. https://doi.org/10.1007/s11892-021-01403-6.

9. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Mela M, et al. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology. 2017;124(4):431–9. https://doi.org/10.1016/j.ophtha.2016.12.005.

10. Shimouchi A, Ishibazawa A, Ishiko S, Omae T, Ro-Mase T, Yang JK. Early Onset Age Increased the Risk of Diabetic Retinopathy in Type 2 Diabetes Patients with Duration of 10–20 Years and HbA1C ≥7%. A Hospital-Based Case-Control Study. Int J Endocrinol. 2021;2021:5539654. https://doi.org/10.1155/2021/5539654.

11. Baek SU, Park MS, Cho BJ, Park IW, Kwon S. Risk factors associated with progression of diabetic retinopathy in eyes treated with ranibizumab photocoagulation. Sci Rep. 2021;11(1):13850. https://doi.org/10.1038/ s41598-021-93384-5.

12. Hsieh YT, Tsai MJ, Tu ST, Hsieh MC. Association of abnormal renal profiles and proliferative diabetic retinopathy and diabetic macular edema in an Asian population with type 2 diabetes. JAMA Ophthalmol. 2018;136(1):68–74. https://doi.org/10.1001/jamaophthalmol.2017.5202.

13. Busik J. Lipid metabolism dysregulation in diabetic retinopathy. J Lipid Res. 2021;62:100017. https://doi.org/10.1194/jlr.R0000981.

14. Li Y, Xu Y, VanderBeek BL. Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy. Eye (Lond). 2020;34(5):934–41. https://doi.org/10.1038/s41433-019-00617-6.

15. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim J, Vemulakonda GA, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127(1):P66-p145. https://doi.org/10.1016/j.jop.2019.09.025.

16. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5):766–85.

17. Vazquez-Moreno M, Loria-Morales D, Peralta-Romero J, Sharma T, Meyre D, Cruz M, et al. AGT rs4762 is associated with diabetic blood pressure in Mexicans with diabetic nephropathy. J Diabetes Complications. 2021;35(3):107826. https://doi.org/10.1016/j.jdiacomp.2020.107826.

18. Xiong XF, Wei L, Xiao Y, Han YC, Yang J, Zhao H, et al. Family history of diabetes is associated with diabetic foot complications in type 2 diabetes. Sci Rep. 2020;10(1):17056. https://doi.org/10.1038/s41598-020-74071-3.

19. Zhang X, Qiu B, Wang Q, Sivapradas S, Wang Y, Zhao L, et al. Dysregulated serum lipid metabolism promotes the occurrence and development of diabetic retinopathy associated with upregulated circulating levels of VEGF-A, VEGF-D, and PIGF. Front Med. 2021;7:779413. https://doi.org/10.3389/fmed.2021.779413.

20. Klein R, Klein BEK. Epidemiology of Ocular Functions and Diseases in Persons With Diabetes. In: rd, Cowie CC, Casagrande SS, Merk A, Cissell MA, Eberhardt MS et al., editors. Diabetes in America. Bethesda; 2018.

21. Vazquez-Moreno M, Loria-Morales D, Peralta-Romero J, Sharma T, Meyre D, Cruz M, et al. AGT rs4762 is associated with diabetic blood pressure in Mexicans with diabetic nephropathy. J Diabetes Complications. 2021;35(3):107826. https://doi.org/10.1016/j.jdiacomp.2020.107826.

22. Xiong XF, Wei L, Xiao Y, Han YC, Yang J, Zhao H, et al. Early-onset type 2 diabetes: A high-risk factor for proliferative diabetic retinopathy (PDR) in patients with microalbuminuria. Medicine (Baltimore). 2020;99(19): e20189. https://doi.org/10.1097/MD.00000000000020189.

23. Liao M, Wang X, Yu J, Meng X, Liu Y, Dong X, et al. Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients. BMC Ophthalmol. 2020;20(1):416. https://doi.org/10.1186/s12886-020-01688-3.

24. Takayama K, Someya H, Yokoyama H, Takamura Y, Morita M, Sameshima S, et al. Risk factors of neovascular glaucoma after 25-gauge vitrectomy for proliferative diabetic retinopathy with vitreous hemorrhage: a retrospective multicenter study. Sci Rep. 2019;9(1):14858. https://doi.org/10.1038/s41598-019-51411-6.

25. Huang CH, Hsieh YT, Yang CM. Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes. Graefe’s Arch Clin Exp Ophthalmol. 2017;255(5):863–71. https://doi.org/10.1007/s00417-016-3579-4.

26. Wykoff CC, Khurana RN, Nguyen QD, Kelly SP, Lum F, Hall R, et al. Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy. Diabetes Care. 2021;44(3):748–56. https://doi.org/10.2337/dc20-0413.

27. Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Mela M, et al. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology. 2017;124(4):431–9. https://doi.org/10.1016/j.ophtha.2016.12.005.

28. Wadhwani M, Bali S, Bhardiya S, Mahabir M, Upadhyaya A, Dada T, et al. Long-term effect of panretinal photocoagulation on retinal nerve fiber layer parameters in patients with proliferative diabetic retinopathy. Oman J Ophthalmol. 2019;12(3):181–5. https://doi.org/10.4103/ajoJO.ajo_39_2018.

29. Wang L, Chen Z, Wang X. Clinical efficacy and acceptability of panretinal photocoagulation combined with conbercept for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(17): e25611. https://doi.org/10.1097/MD.0000000000025611.

30. Yuan J, Zhang L, Jia P, Xin Z, Yang JK. Early Onset Age Increased the Risk of Diabetic Retinopathy in Type 2 Diabetes Patients with Duration of 10–20
33. Sasso FC, Pafundi PC, Gelso A, Bono V, Costagliola C, Marfella R, et al. Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from a No blind study. Nutr Metab Cardiovasc Dis. 2019;29(9):923–30. https://doi.org/10.1016/j.numecd.2019.05.065.

34. Lin W, Luo Y, Liu F, Li H, Wang Q, Dong Z, et al. Status and trends of the association between diabetic nephropathy and diabetic retinopathy from 2000 to 2021: bibliometric and visual analysis. Front Pharmacol. 2022;13:93759. https://doi.org/10.3389/fphar.2022.93759.

35. Yang J, Liu Z. Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne). 2022;13:816400. https://doi.org/10.3389/fendo.2022.816400.

36. Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015;22(2):151–6. https://doi.org/10.4103/0974-9233.154388.

37. Chou Y, Ma J, Su X, Zhong Y. Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. Lipids Health Dis. 2020;19(1):241. https://doi.org/10.1186/s12944-020-01415-3.

38. Murakami T, Kato S, Shigematsu T, Itoh H, Komuro I, Takeuchi M, et al. Intensive treat-to-target statin therapy and severity of diabetic retinopathy complicated by hypercholesterolaemia. Eye (Lond). 2021;35(8):2221–8. https://doi.org/10.1038/s41433-020-01202-5.

39. Liu J, Wu YP, Qi JJ, Yue ZP, Hu CD. Effect of statin therapy on diabetes retinopathy in people with type 2 diabetes mellitus: a meta-analysis. Clin Appl Thromb Hemost. 2021;27:1076026211040109. https://doi.org/10.1177/10760262211040109.

40. Srinivasan S, Raman R, Kulothungan V, Swaminathan G, Sharma T. Influence of serum lipids on the incidence and progression of diabetic retinopathy and macular oedema: Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular genetics Study-II. Clin Experiment Ophthalmol. 2017;45(9):894–900. https://doi.org/10.1111/ceo.12990.

41. Sun Z, Tang F, Wong R, Lok J, Szeto SKH, Chan JCK, et al. OCT angiography metrics predict progression of diabetic retinopathy and development of diabetic macular edema: a prospective study. Ophthalmology. 2019;126(12):1675–84. https://doi.org/10.1016/j.ophtha.2019.06.016.

42. Li W, Song Y, Chen K, Ying J, Zheng Z, Qiao S, et al. Predictive model and risk analysis for diabetic retinopathy using machine learning: a retrospective cohort study in China. BMJ Open. 2021;11(1):e050989. https://doi.org/10.1136/bmjopen-2021-050989.

43. Jiang W, Wang J, Shen X, Lu W, Wang Y, Li W, et al. Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 Cohorts. Diabetes Care. 2020;43(4):925–33. https://doi.org/10.2337/dci19-1897.

44. Shi L, Wei H, Zhang T, Li Z, Chi X, Liu D, et al. A potent weighted risk model for evaluating the occurrence and severity of diabetic foot ulcers. Diabetol Metab Syndr. 2021;13(1):92. https://doi.org/10.1186/s13098-021-00771-x.

45. Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. https://doi.org/10.1038/nrdp.2016.12.

46. Krakauer M, Botero JF, Lavalle-Gonzalez FJ, Proietti A, Barbieri DE. A review of flash glucose monitoring in type 2 diabetes. Diabetol Metab Syndr. 2021;13(1):42. https://doi.org/10.1186/s13098-021-00654-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.